Browse NEK2

Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Nucleus. Nucleus, nucleolus Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle pole. Chromosome, centromere, kinetochore. Chromosome, centromere Note=STK3/MST2 and SAV1 are required for its targeting to the centrosome. Colocalizes with SGO1 and MAD1L1 at the kinetochore. Not associated with kinetochore in the interphase but becomes associated with it upon the breakdown of the nuclear envelope. Has a nucleolar targeting/ retention activity via a coiled-coil domain at the C-terminal end.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Predominantly cytoplasmic.; SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Predominantly nuclear.
Domain PF00069 Protein kinase domain
Function

Protein kinase which is involved in the control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. Regulates centrosome separation (essential for the formation of bipolar spindles and high-fidelity chromosome separation) by phosphorylating centrosomal proteins such as CROCC, CEP250 and NINL, resulting in their displacement from the centrosomes. Regulates kinetochore microtubule attachment stability in mitosis via phosphorylation of NDC80. Involved in regulation of mitotic checkpoint protein complex via phosphorylation of CDC20 and MAD2L1. Plays an active role in chromatin condensation during the first meiotic division through phosphorylation of HMGA2. Phosphorylates: PPP1CC; SGO1; NECAB3 and NPM1. Essential for localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the centrosome. Phosphorylates CEP68 and CNTLN directly or indirectly (PubMed:24554434). NEK2-mediated phosphorylation of CEP68 promotes CEP68 dissociation from the centrosome and its degradation at the onset of mitosis (PubMed:25704143). Involved in the regulation of centrosome disjunction (PubMed:26220856). ; FUNCTION: Isoform 1: Phosphorylates and activates NEK11 in G1/S-arrested cells. ; FUNCTION: Isoform 2: Not present in the nucleolus and, in contrast to isoform 1, does not phosphorylate and activate NEK11 in G1/S-arrested cells.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000226 microtubule cytoskeleton organization
GO:0000723 telomere maintenance
GO:0000819 sister chromatid segregation
GO:0001701 in utero embryonic development
GO:0001824 blastocyst development
GO:0006278 RNA-dependent DNA biosynthetic process
GO:0007004 telomere maintenance via telomerase
GO:0007051 spindle organization
GO:0007059 chromosome segregation
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007098 centrosome cycle
GO:0007100 mitotic centrosome separation
GO:0007346 regulation of mitotic cell cycle
GO:0008608 attachment of spindle microtubules to kinetochore
GO:0010457 centriole-centriole cohesion
GO:0010639 negative regulation of organelle organization
GO:0010833 telomere maintenance via telomere lengthening
GO:0016233 telomere capping
GO:0030997 regulation of centriole-centriole cohesion
GO:0031023 microtubule organizing center organization
GO:0032200 telomere organization
GO:0032204 regulation of telomere maintenance
GO:0032206 positive regulation of telomere maintenance
GO:0032210 regulation of telomere maintenance via telomerase
GO:0032212 positive regulation of telomere maintenance via telomerase
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032886 regulation of microtubule-based process
GO:0033044 regulation of chromosome organization
GO:0043392 negative regulation of DNA binding
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0046602 regulation of mitotic centrosome separation
GO:0046605 regulation of centrosome cycle
GO:0046777 protein autophosphorylation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051225 spindle assembly
GO:0051297 centrosome organization
GO:0051299 centrosome separation
GO:0051321 meiotic cell cycle
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051783 regulation of nuclear division
GO:0051972 regulation of telomerase activity
GO:0051973 positive regulation of telomerase activity
GO:0051983 regulation of chromosome segregation
GO:0051988 regulation of attachment of spindle microtubules to kinetochore
GO:0060249 anatomical structure homeostasis
GO:0070507 regulation of microtubule cytoskeleton organization
GO:0071897 DNA biosynthetic process
GO:0090307 mitotic spindle assembly
GO:0098813 nuclear chromosome segregation
GO:1902850 microtubule cytoskeleton organization involved in mitosis
GO:1903126 negative regulation of centriole-centriole cohesion
GO:1904353 regulation of telomere capping
GO:1904355 positive regulation of telomere capping
GO:1904356 regulation of telomere maintenance via telomere lengthening
GO:1904358 positive regulation of telomere maintenance via telomere lengthening
GO:2000278 regulation of DNA biosynthetic process
GO:2000573 positive regulation of DNA biosynthetic process
GO:2001252 positive regulation of chromosome organization
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000922 spindle pole
GO:0005813 centrosome
GO:0005819 spindle
GO:0005874 microtubule
GO:0030496 midbody
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-179409: APC-Cdc20 mediated degradation of Nek2A
R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-176409: APC/C
R-HSA-179419: APC
R-HSA-8854518: AURKA Activation by TPX2
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-5617833: Cilium Assembly
R-HSA-69275: G2/M Transition
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-453276: Regulation of mitotic cell cycle
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NEK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NEK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NEK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.40.139
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3020.821
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4720.642
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.540.268
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6330.624
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4270.799
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1250.752
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.8110.515
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7230.568
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0030.997
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0070.995
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5964.59e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NEK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NEK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NEK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NEK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NEK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NEK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NEK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNEK2
NameNIMA-related kinase 2
Aliases NLK1; NEK2A; RP67; PPP1R111; HsPK 21; protein phosphatase 1, regulatory subunit 111; NIMA (never in mitosis ......
Chromosomal Location1q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NEK2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NEK2.
ID Name Drug Type Targets #Targets
DB071805-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamideSmall MoleculeNEK21